Meyka Pro banner
Gilead Sciences, Inc.

Gilead Sciences, Inc. (GILD) Stock Overview

Explore Gilead Sciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

GILD●NASDAQ
HealthcareDrug Manufacturers - General
$166.43
$0.10(0.06%)
U.S. Market opens in 64h 20m

Gilead Sciences, Inc. (GILD)

Meyka AI Score

Z

Key Financials

Market Cap206.6B
P/E Ratio-53.71
EPS (TTM)$-0.39
ROE-0.22%
Fundamental Analysis

AI Price Forecasts

1 Month$175.02
3 Months$164.99
1 Year Target$162.10

GILD Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Gilead Sciences, Inc. (NASDAQ: GILD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Gilead Sciences, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GILD on the NASDAQ shows an RSI of 55.88, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $162.10 for the NASDAQ listing.

Key metrics behind Gilead Sciences, Inc.'s NASDAQ-traded stock include a P/E ratio of -53.71 and a market capitalization of 206.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of GILD on the NASDAQ.

Price Performance (NASDAQ: GILD)

1-Day Change
-0.06%
5-Day Change
-1.28%
1-Month Change
6.34%
3-Month Change
16.03%
6-Month Change
27.35%
Year-to-Date (YTD) Change
35.60%
1-Year Change
33.15%
3-Year Change
118.99%
5-Year Change
137.86%
All-Time (Max) Change
26200.15%

Contact Information

650 574 3000
333 Lakeside Drive, Foster City, CA, 94404

Company Facts

170,000 Employees
IPO DateJan 22, 1992
CountryUS
Actively Trading

Frequently Asked Questions